Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zemaira in Eosinophilic Esophagitis
NCT05485155Phase 2Recruiting
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- May 2025
- Primary completion
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of alpha-1-proteinase inhibitor in eosinophilic esophagitis (EoE), sponsored by Cincinnati Children's Hospital Medical Center. Started May 2025; status: recruiting.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT05485155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05485155.